A new consensus on blood-test intervals for long-term rheumatic disease treatment
A recent consensus study has established a risk-stratified framework for monitoring patients on long-term conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for systemic autoimmune rheumatic diseases (SARDs). Using the RAND/UCLA Appropriateness Method, a panel of 21 clinicians, including consultants, specialist nurses, and pharmacists, evaluated the appropriateness of different intervals between monitoring blood tests based on a patient’s predicted five-year risk of discontinuing treatment due to adverse drug reactions. The panel reached a clear consensus: for patients with a predicted risk of 10% or less, six-monthly blood tests are appropriate, while for those with a risk greater than 10%, the monitoring interval should be shortened to three-monthly tests. This work provides a practical, evidence-based threshold to guide safer and more efficient long-term management of SARDs.
Why it might matter to you: This consensus directly addresses a core clinical dilemma in rheumatology: balancing patient safety against the burden of frequent monitoring. The proposed risk-stratified approach offers a data-driven method to optimize monitoring schedules for established csDMARD therapy, potentially reducing unnecessary healthcare visits for low-risk patients while ensuring closer surveillance for those at higher risk of haematological, hepatic, or renal adverse events. Implementing this framework could streamline clinical workflows and enhance the personalization of long-term care for conditions like rheumatoid arthritis and lupus.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
